Menu

Oncotarget Journal Cut from Medline

New papers from a cancer journal once named as a possibly predatory publication will no longer appear in the widely used research database.

Oct 26, 2017
Katarina Zimmer

ISTOCK, FACTORYTHMedline—a government biomedical research database—no longer lists new research articles from a cancer journal with a troubled reputation. 

Oncotarget, published by Impact Journals, was included in a now-inactive list of “possible predatory publishers” maintained by Jeffrey Beall, a librarian at the University of Colorado Denver. Beall has criticized Oncotarget’s peer review process as “questionable.”  

According to Retraction Watch, Oncotarget has issued “a handful” of recent retractions. This includes a paper published earlier this year on the genetics that underlie the development of cancer that was reportedly pulled due to “data errors” and “negligence.” Retraction Watch reports that the editor-in-chief, Mikhail Blagosklonny, considered retracting the research papers of Beall’s colleagues after the journal had been added to Beall’s list and Beall alerted the journal to potential problems with the publications. 

Medline is maintained by the U.S. National Library of Medicine, which gave no explanation as to why the journal was removed, according to Retraction Watch. However, papers published in Oncotarget will remain available on Pubmed, one of the most popular search tools for biomedical literature.

Beall coined the term predatory publishing to describe journals the exploit the open-access publishing model by collecting fees for publication that are well below those charged by legitimate open-access journals. Beall told The Scientist earlier this year, “They try to trick honest researchers, and sometimes they are successful.” 

Correction (November 15): Oncotarget’s legal representation alerted us to several inaccuracies, which we have clarified. The first paragraph now states that new articles are no longer listed in Medline. The third paragraph clarifies that it was Beall who had alerted Oncotarget to possible problems in his colleagues’ papers, and that Blagosklonny had considered retracting them. The Scientist regrets the errors.

Correction (November 17): The subheading to the article was clarified to also note that only new papers are de-listed from Medline and that Bealls list referred to journals as possibly predatory.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.